Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:GANX NASDAQ:HUMA NASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.48-0.4%$6.13$3.93▼$7.54$281.27M1.421.00 million shs392,182 shsGANXGain Therapeutics$2.00+4.2%$1.81$1.41▼$2.81$71.86M0.11375,442 shs564,071 shsHUMAHumacyte$1.74-4.1%$1.67$1.15▼$6.77$274.78M1.894.29 million shs1.76 million shsSOPHSOPHiA GENETICS$4.10-2.1%$3.71$2.58▼$4.92$277.08M1.177,594 shs16,109 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+2.23%+1.66%+2.23%-15.64%-17.54%GANXGain Therapeutics+2.67%+1.05%+21.52%+18.52%-28.89%HUMAHumacyte+5.23%+2.84%-2.69%-21.30%-64.02%SOPHSOPHiA GENETICS-2.78%+3.71%+26.20%+22.16%+16.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.48-0.4%$6.13$3.93▼$7.54$281.27M1.421.00 million shs392,182 shsGANXGain Therapeutics$2.00+4.2%$1.81$1.41▼$2.81$71.86M0.11375,442 shs564,071 shsHUMAHumacyte$1.74-4.1%$1.67$1.15▼$6.77$274.78M1.894.29 million shs1.76 million shsSOPHSOPHiA GENETICS$4.10-2.1%$3.71$2.58▼$4.92$277.08M1.177,594 shs16,109 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+2.23%+1.66%+2.23%-15.64%-17.54%GANXGain Therapeutics+2.67%+1.05%+21.52%+18.52%-28.89%HUMAHumacyte+5.23%+2.84%-2.69%-21.30%-64.02%SOPHSOPHiA GENETICS-2.78%+3.71%+26.20%+22.16%+16.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.83Moderate Buy$19.50255.84% UpsideGANXGain Therapeutics 2.75Moderate Buy$7.86292.86% UpsideHUMAHumacyte 2.71Moderate Buy$8.71402.26% UpsideSOPHSOPHiA GENETICS 2.00Hold$8.0095.12% UpsideCurrent Analyst Ratings BreakdownLatest GANX, SOPH, HUMA, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025GANXGain TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.0010/13/2025HUMAHumacyteUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.0010/13/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.0010/13/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.0010/13/2025HUMAHumacyteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.0010/8/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025GANXGain TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025HUMAHumacyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SOPHSOPHiA GENETICSWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025GANXGain TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.0010/6/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M80.29N/AN/A$1.01 per share5.43GANXGain Therapeutics$50K1,438.00N/AN/A$0.28 per share7.14HUMAHumacyte$818K335.91N/AN/A($0.41) per share-4.23SOPHSOPHiA GENETICS$69.69M3.98N/AN/A$1.48 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.707.84N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)HUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$0.44N/AN/AN/A-40.99%-30.69%-17.39%11/4/2025 (Estimated)Latest GANX, SOPH, HUMA, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025HUMAHumacyte-$0.17N/AN/AN/A$0.92 millionN/A11/13/2025Q3 2025ABEOAbeona Therapeutics-$0.27N/AN/AN/A$5.53 millionN/A11/13/2025Q3 2025GANXGain Therapeutics-$0.15N/AN/AN/AN/AN/A11/4/2025Q3 2025SOPHSOPHiA GENETICS-$0.20N/AN/AN/A$18.13 millionN/A8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/A8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million8/5/2025Q2 2025SOPHSOPHiA GENETICS-$0.25$0.33+$0.58$0.33$17.49 million$18.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65GANXGain Therapeutics0.091.791.79HUMAHumacyte2.972.451.93SOPHSOPHiA GENETICS0.623.393.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%GANXGain Therapeutics11.97%HUMAHumacyte44.71%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%GANXGain Therapeutics7.18%HUMAHumacyte5.10%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million48.51 millionOptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableHUMAHumacyte150158.37 million150.30 millionOptionableSOPHSOPHiA GENETICS52067.58 million64.28 millionNot OptionableGANX, SOPH, HUMA, and ABEO HeadlinesRecent News About These CompaniesSOPHiA GENETICS to Announce Financial Results for Third Quarter 2025 on November 4, 2025October 21 at 8:00 AM | prnewswire.comSOPHiA GENETICS introduces AI-powered Digital Twins to enhance intelligent decision-making in oncologyOctober 19 at 4:48 PM | pharmabiz.comPSophia Genetics, A.D.A.M Genetics partner for liquid biopsy testingOctober 16, 2025 | msn.comA.D.A.M. Innovations and SOPHiA GENETICS partner to advance liquid biopsy testing and companion diagnostics for precision oncology in JapanOctober 16, 2025 | prnewswire.comSOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in OncologyOctober 16, 2025 | prnewswire.comWeiss Ratings Reaffirms Sell (D-) Rating for SOPHiA GENETICS (NASDAQ:SOPH)October 9, 2025 | marketbeat.comWhat to know about breast cancer genetic testingOctober 8, 2025 | msn.comSOPHiA GENETICS SA Trends on Nasdaq 100 Index PerformanceOctober 4, 2025 | kalkinemedia.comKSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateOctober 4, 2025 | marketbeat.com3 Penny Stocks With Market Caps Over $100M And Promising GrowthSeptember 23, 2025 | finance.yahoo.comMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsySeptember 23, 2025 | prnewswire.comMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid BiopsySeptember 23, 2025 | globenewswire.comSophia Genetics management to meet with Craig-HallumSeptember 22, 2025 | msn.comSOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate CancerSeptember 22, 2025 | prnewswire.comSophia Genetics management to meet virtually with Craig-HallumSeptember 17, 2025 | msn.comSOPHiA Genetics & Jessa Ziekenhuis partner to bring cutting edge genomic testing and oncology research to cancer patients across BelgiumSeptember 8, 2025 | pharmabiz.comPJessa Ziekenhuis to adopt SOPHiA GENETICS platform for cancer careSeptember 8, 2025 | finance.yahoo.comSOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership from the European Congress of PathologySeptember 5, 2025 | prnewswire.comSophia Genetics Growth Story Clouded By Persistent Losses: Why I'm Choosing To HoldAugust 26, 2025 | seekingalpha.comSOPHiA GENETICS SA: Positive Earnings Call HighlightsAugust 14, 2025 | theglobeandmail.comSOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGANX, SOPH, HUMA, and ABEO Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.48 -0.02 (-0.36%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Gain Therapeutics NASDAQ:GANX$2.00 +0.08 (+4.17%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Humacyte NASDAQ:HUMA$1.74 -0.08 (-4.14%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.SOPHiA GENETICS NASDAQ:SOPH$4.10 -0.09 (-2.15%) As of 01:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
